Page 23 - JCTR-11-4

Journal of Clinical and
Translational Research Hidden cancer after VTE

A post hoc analysis of the hokusai-VTE study. Thromb recommendations#investigations/for/cancer [Last accessed
Haemost. 2018;118(7):1270-1278. on 2024 Feb 24].
doi: 10.1055/s-0038-1649523 37. Screening for Occult Malignancy in Patients With Unprovoked
Venous Thromboembolism (MVTEP2/SOME2). Available
31. Mulder FI, Carrier M, Van Doormaal F, et al. Risk scores
for occult cancer in patients with unprovoked venous from: https://clinicaltrials.gov/study/nct04304651?cond=nc
thromboembolism: Results from an individual patient data t04304651&rank=1 [Last accessed on 2024 Jan 14].
meta‐analysis. J Thromb Haemost. 2020;18(10):2622-2628. 38. Mrozinska S, Cieslik J, Broniatowska E, Malinowski KP, Undas A.
Prothrombotic fibrin clot properties associated with increased
doi: 10.1111/jth.15001
endogenous thrombin potential and soluble P-selectin predict
32. Franco-Moreno A, Morejón-Girón JB, Agudo-Blas P, et al. occult cancer after unprovoked venous thromboembolism.
External validation of the RIETE and SOME scores for J Thromb Haemost. 2019;17(11):1912-1922.
occult cancer in patients with venous thromboembolism:
A multicentre cohort study. Clin Transl Oncol. 2024; doi: 10.1111/jth.14579
26:2685-2692. 39. Sánchez-López V, Marín-Romero S, Ferrer-Galván M,
et al. Occult cancer in patients with unprovoked venous
doi: 10.1007/s12094-024-03500-w
thromboembolism: A nested case-control study. Am J Clin
33. Klein A, Shepshelovich D, Spectre G, Goldvaser H, Pathol. 2024;161:501-511.
Raanani P, Gafter-Gvili A. Screening for occult cancer in
idiopathic venous thromboembolism - systemic review and doi: 10.1093/ajcp/aqad178
meta-analysis. Eur J Intern Med. 2017;42:74-80. 40. Kraaijpoel N, Mulder FI, Carrier M, et al. Novel biomarkers
to detect occult cancer in patients with unprovoked venous
doi: 10.1016/j.ejim.2017.05.007
thromboembolism: Rationale and design of the PLATO-
34. Robertson L, Yeoh SE, Stansby G, Agarwal R. Effect of testing VTE study. Thromb Update. 2021;2:100030.
for cancer on cancer- and venous thromboembolism (VTE)-
related mortality and morbidity in patients with unprovoked doi: 10.1016/j.jtha.2023.01.003
VTE. Cochrane Database Syst Rev. 2015;6(3):CD010837. 41. Franco-Moreno A, Madroñal-Cerezo E, Muñoz-
Rivas N, Torres-Macho J, Ruiz-Giardín JM, Ancos-
doi: 10.1002/14651858.CD010837.pub2
Aracil CL. Prediction of venous thromboembolism in
35. Delluc A, Antic D, Lecumberri R, Ay C, Meyer G, patients with cancer using machine learning approaches:
Carrier M. Occult cancer screening in patients with venous A systematic review and meta-analysis. JCO Clin Cancer
thromboembolism: Guidance from the SSC of the ISTH. Inform. 2023;7:e2300060.
J Thromb Haemost. 2017;15(10):2076-2079.
doi: 10.1200/CCI.23.00060
doi: 10.1111/jth.13791
42. Muñoz AJ, Souto JC, Lecumberri R, et al. Development of
36. Venous Thromboembolic Diseases: Diagnosis, Management a predictive model of venous thromboembolism recurrence
and Thrombophilia Testing. London: National Institute in anticoagulated cancer patients using machine learning.
for Health and Care Excellence (NICE); 2023. Available Thromb Res. 2023;228:181-188.
from: https://www.nice.org.uk/guidance/ng158/chapter/
doi: 10.1016/j.thromres.2023.06.015R

Volume 11 Issue 4 (2025) 17 doi: 10.36922/jctr.24.00069